Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average of $2.25

Galectin Therapeutics Inc. (NASDAQ:GALT) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.25 and traded as high as $3.28. Galectin Therapeutics shares last traded at $3.16, with a volume of 158,522 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on GALT shares. StockNews.com upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Galectin Therapeutics in a research report on Tuesday, April 9th.

Galectin Therapeutics Trading Down 3.7 %

The stock has a market cap of $193.29 million, a P/E ratio of -4.20 and a beta of 0.72. The firm’s 50-day simple moving average is $3.08 and its 200 day simple moving average is $2.27.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). On average, analysts anticipate that Galectin Therapeutics Inc. will post -0.66 EPS for the current year.

Insider Activity

In other news, major shareholder James C. Czirr sold 21,323 shares of the stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $3.06, for a total value of $65,248.38. Following the completion of the transaction, the insider now directly owns 5,925,884 shares in the company, valued at $18,133,205.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 4,500 shares of company stock worth $14,360 over the last three months. Corporate insiders own 52.70% of the company’s stock.

Institutional Trading of Galectin Therapeutics

Large investors have recently added to or reduced their stakes in the business. Retirement Guys Formula LLC boosted its holdings in Galectin Therapeutics by 87.0% during the fourth quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company’s stock worth $36,000 after buying an additional 10,000 shares in the last quarter. Beacon Capital Management LLC boosted its holdings in Galectin Therapeutics by 89.6% during the fourth quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock worth $40,000 after buying an additional 11,300 shares in the last quarter. Solutions 4 Wealth Ltd bought a new stake in Galectin Therapeutics during the fourth quarter worth approximately $60,000. D.A. Davidson & CO. boosted its holdings in Galectin Therapeutics by 15.2% during the third quarter. D.A. Davidson & CO. now owns 37,825 shares of the company’s stock worth $73,000 after buying an additional 5,000 shares in the last quarter. Finally, Wealthspire Advisors LLC lifted its position in shares of Galectin Therapeutics by 116.7% in the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock valued at $952,000 after acquiring an additional 214,512 shares in the last quarter. 11.68% of the stock is currently owned by institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.